| HOME >> MEDICINE >> TECHNOLOGY |
Product analysis, 2002-08 35
Product analysis, 2008-14 37
Therapy area analysis 40
Geographic analysis 43
Launch/core/expiry analysis 45
Explanation of launch/core/expiry analysis 45
Launch analysis, 2008-14 46
Core analysis, 2008-14 49
Expiry analysis, 2008-14 50
Launch/core/expiry configuration, 2008-14 52
Molecule type analysis 53
Externalization analysis 55
Chapter 6 Company financials 57
Key findings 57
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002-08 58
Operating costs and profit analysis 60
Operating costs and profit analysis, 2002-08 61
Operating cost ratio and profit margin analysis, 2002-08 62
Operating cost ratio and profit margin analysis, 2008-14 63
Operating costs and profit analysis, 2008-14 64
Chapter 7 Key products and competitors 66
Key findings 66
Overview 67
Central nervous system 68
Botox 68
Overview 68
Sales forecast 69
Other (ophthalmology) 71
Restasis 71
Overview 71
Sales forecast 72
Lumigan franchise 73
Overview 73
Sales forecast 74
Alphagan franchise 76
Overview 76
Sales forecast 77
Ozurdex 79
Overview 79
Sales forecast 80
Ozurdex offers significant benefits over the standard of care 81
Other (skin care) 82
Latisse 82
Overview 82
Sales forecast 83
Chapter 8 Appendix 84
R&D pipeline 84
Reconciliation with reported figures 85
References 86
Abbreviations 86
Exchange rates 87
About Datamonitor 88
'/>"/>| SOURCE Reportlinker Copyright©2009 PR Newswire. All rights reserved |